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Abstract
Background: Lung cancer remains a major health challenge in the world. Survival for patients with
stage I disease ranges between 40–70%. This suggests that a significant proportion of patients with
stage I NSCLC may actually be under-staged.
Methods: In order to identify genes relevant for lung cancer development, we carried out cDNA
array experiments employing 64 consecutive patients (58 men and 6 women) with a median age of
58 years and stage 1 or stage 2 non-small-cell lung cancer (NSCLC).
Results: Basic cDNA array data identified 14 genes as differentially regulated in the two groups.
Quantitative RT-PCR analysis confirmed an effective different transcriptional regulation of 8 out of
14 genes analyzed. The products of these genes belong to different functional protein types, such
as extra-cellular matrix proteins and proteases (Decorin and MMP11), genes involved in DNA repair
(XRCC1), regulator of angiogenesis (VEGF), cell cycle regulators (Cyclin D1) and tumor-suppressor
genes (Semaphorin 3B, WNT-5A and retinoblastoma-related Rb2/p130). Some previously described
differences in expression patterns were confirmed by our array data. In addition, we identified and
validated for the first time the reduced expression level of some genes during lung cancer
progression.
Conclusion: Comparative hybridization by means of cDNA arrays assisted in identifying a series
of novel progression-associated changes in gene expression, confirming, at the same time, a number
of previously described results.
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Introduction
Lung cancer remains a major health challenge in the
world. Despite improvements in staging and the inte-
grated application of surgery, radiotherapy, and chemo-
therapy, the 5-year survival rate for individuals with lung
cancer is only about 15% [1]. Histologically, 80% of the
lung cancers are diagnosed as non-small-cell lung cancer
(NSCLC), whereas the remaining 20% of cases are diag-
nosed as small-cell lung cancer (SCLC). On the basis of
cell morphology, adenocarcinoma and squamous cell car-
cinoma are the most common types of NSCLC. The cur-
rent staging system for NSCLC is based upon the size and
location of the primary tumor (T), the involvement of
regional lymph nodes (N), and the presence of distant
metastases (M) [1]. The standard treatment of patients
with stage I NSCLC (T1-2, N0, M0) is resection of the pri-
mary tumor alone (no adjuvant therapy) [2]. Survival for
patients with stage I disease ranges between 40–70%, and
the failure is due to distant recurrences [3]. This suggests
that a significant proportion of patients with stage I
NSCLC may actually be under-staged. Therefore, if cor-
rectly identified, these patients may benefit from adjuvant
therapy in addition to resection, with a predictable
improvement in the survival rates. Indeed, to identify
patients with stage I NSCLC who might benefit from adju-
vant therapy, investigators have attempted to identify fac-
tors predicting poor prognosis. These studies included
analysis of performance status, histologic subtype, size of
the primary tumor, the degree of tumor differentiation,
mitotic rate, and evidence of lymphatic or vascular inva-
sion [4-8]. However, all of these factors have failed, to
date, to precisely identify a group of stage I patients who
would benefit from adjuvant therapy. Cigarette smoking
remains the main risk factor for lung cancer, accounting
for about 90% of the cases in men and 70% of the cases in
women [9]. Our research group has investigated in the last
years the possible involvement of several molecular mech-
anisms, such as cell cycle and apoptosis regulators, onco-
genes and tumor suppressor genes, cell adhesion
molecules, in the pathogenesis and progression of lung
cancer [10-19].
In this study, we utilized the cDNA array technique to
identify genes differently expressed in patients at early
stage of NSCLC.
Materials and methods
Patient selection
Table 1 summarizes the characteristics of the patients
enrolled in the study. Subjects selected for the analysis
were 64 patients, consecutively treated at the Department
of Thoracic Surgery of the Tor Vergata University in Rome,
who had radical surgery for NSCLC at pathological stage
1 or 2. The study project was submitted and approved by
the Human Tissue Use Committee of the University. The
patients were staged according to operative and patholog-
ical findings based on AJCC/UICC-TNM classification and
stage grouping [17]. N-factor was assessed on lymph
nodes removed during routine mediastinal lymphadenec-
tomy. A preoperative staging computed tomography (CT)
scan was performed in all patients. Histology grading and
N-stage were performed on haematoxylin-eosin stained
sections. In 22 patients the neoplasm was resected by
pneumonectomy and in 42 by lobectomy. Patients who
did not survive beyond 60 days after surgery were not
included in the study to avoid bias from peri-operative
death. Patients who underwent minimal resection were
ruled out from the present analysis. Another mandatory
prerequisite, was the lack of chemo or radiotherapy before
and after surgical resection.
RNA extraction
Total RNA from frozen tumour tissues was extracted uti-
lizing the Atlas™ Pure Total RNA Extraction System
(CLONTECH). RNAs were quantified spectrophotometri-
cally and their integrity confirmed by fractionation of 1 μg
of RNA on 1% agarose gel with ethidium bromide stain-
ing. Then, two populations of RNAs were prepared,
including exactly 1 μg of RNA from each patients, separat-
ing patients in stage 1 and stage 2.
Array hybridization
We prepared cRNA for hybridization using the Atlas™ Pure
Total RNA labeling System (Clontech). The Clontech
Atlas™ Human Cancer Array, composed of 588 human
cDNAs, was used for hybridization according to the man-
ufacturer's instructions. Arrays were scanned using a Phos-
phorImager and analyzed by ImageQuant 5.0 software
(Molecular Dynamics, Sunnyvale, California). The exper-
iment was performed in duplicate, utilizing two different
RNA preparations. Intensity values were normalized using
the expression levels of the housekeeping genes spotted
Table 1: Patients' Characteristics
Total number 64
Median age 58
Male vs Female 58 vs 6 (90.5% vs 9.5%)
Neoplasm histotype
Squamous cell carcinoma 33 (51.5%)
Adenocarcinoma 23 (36%)
Others 8 (12.5%)
Clinical Stage
I 42 (65.5%)
II 22 (34.5%)
Grading
1–2 38 (59.5%)
3 26 (40.5%)
Surgery
Pneumectomy 22 (34.5%)
Lobectomy 42 (65.5%)Journal of Experimental & Clinical Cancer Research 2008, 27:38 http://www.jeccr.com/content/27/1/38
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on the arrays. A cut-off of two folds was used to select the
genes differentially expressed.
Quantitative real-time reverse transcription-PCR
The primer sequences are shown in table 2. Primers were
designed using Primer Express 2.0 software (Applied Bio-
system, Foster City, CA, USA). The specificity of each tar-
get amplicon was assessed by dissociation curve analysis
and all amplicons were spanning over exon-exon regions
to avoid genomic amplification. qPCR was performed on
an ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems, CA, USA) in 384 well plates assem-
bled by Biorobot 8000 (Qiagen, Hilden, Germany) using
a final volume of 20 μl and the following cycle conditions:
50°C for 2 min., 95°C for 10 min., and then 40 cycles of
15 s at 95°C and 1 min at 60°C. All QPCR mixtures con-
tained 1 μl of cDNA template (corresponding to 20 ng
retro-transcribed totRNA), 1× Sybr Green PCR Master Mix
(2×) (Applied Biosystems, CA, USA) and 150 μM of each
target-specific primer. For each experiment a no-template
reaction was included as negative control. Results have
been analyzed using the Applied Biosystems analysis soft-
ware and expression levels calculated from a linear regres-
sion of the standard curve. Results are given as gene target
expression vs GADPH expression (gene target relative
expression) to correct for differences in the quantity of
cDNA used in the PCR reaction. All real-time PCR reac-
tions for each sample were performed in triplicate.
Results
A typical representation of the results obtained hybridiz-
ing two identical filter arrays with cDNA-labeled probes
generated from either patients in stage 1 and patients in
stage 2 is shown in Figure 1, Panels A and B. Computer-
assisted analysis of these filters allowed, after normaliza-
tion, to identify 14 genes, out of 588, as differentially reg-
ulated in the two groups (data not shown). To confirm
these changes in expression patterns, the genes were fur-
ther analyzed by Quantitative RT-PCR, using two sets of
independently prepared RNAs. Only 8 out of 14 of the
genes analyzed were confirmed to be differentially regu-
lated by quantitative RT-PCR. In table 2 are depicted the
genes whose differential expression was confirmed with
quantitative RT-PCR. In table 3 the primers utilized for
RT-PCR are shown. These genes code for different protein
families: extra-cellular matrix proteins and proteases
(Decorin  and  MMP11), genes involved in DNA repair
(XRCC1), regulator of angiogenesis (VEGF), cell cycle reg-
ulators (Cyclin D1) and tumor-suppressor genes (Sema-
phorin 3B,  WNT-5A  and retinoblastoma-related Rb2/
p130).
Discussion
In the present study, we analyzed two population of
NSCLC patients at stage 1 and 2 to screen for tumor pro-
gression-associated genes, by means of a cDNA array filter
containing 588 different cDNAs. Consistent with previ-
ously reported results [20], not all of the differences found
by the array were effectively reproducible using another
quantitative mRNA technique, such as quantitative RT-
PCR. The discrepancies could be explained by methodo-
logical limitations of the array technology, where thou-
sands of diverse cDNAs differing exponentially in
expression levels are compared by means of a single
hybridization reaction, irrespective of the optimal range
of reaction conditions.
The genes we found reliably differentially regulated in the
two RNA populations are known to exert different func-
tions, thus confirming that the biological events taking
place during the malignant progression involve several
molecular pathways.
The cyclin D1 gene codes for one of the cyclins involved in
cell cycle regulation; specifically for the G1-S transition.
The involvement of cell-cycle regulators in the progression
of lung cancer is well documented [21]. This observation,
therefore, further support the fact that alterations in cell
cycle regulation is one of the earlier steps in the progres-
sion of NSCLC.
The VEGF gene codes for a glycoprotein with potent ang-
iogenic, mitogenic, and vascular permeability-enhancing
activities for endothelial cells. Tumour neoangiogenesis
has been recently recognized to be of importance in defin-
ing subsets of patients with poor outcome in cancer
Table 2: Expression patterns obtained by array hybridization and confirmation of differential gene expression by Quantitative RT-PCR
Gene Ref seq ID Array ratio Stage 1/stage 2 Confirmed by QPCR
Cyclin D1 NM_053056 2.04 down Yes
VEGF NM_003376 2.02 up Yes
WNT-5A NM_003392 2.03 down Yes
MMP11 NM_005940 3.68 up Yes
Rb2/p130 NM_005611 3.24 down Yes
Semaphorin NM_004263 3.43 down Yes
Decorin NM_001920 2.16 up Yes
XRCC1 NM_006297 3.40 down YesJournal of Experimental & Clinical Cancer Research 2008, 27:38 http://www.jeccr.com/content/27/1/38
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[22,23]. From that several reports [18,24] have stated that
the presence of neoangiogenesis represents a significant
factor in terms of overall and disease free survival in lung
cancer.
The WNT-5A gene is a representative ligand that activates
a beta-catenin-independent pathway in the Wnt signalling
[25]. In contrast to the transforming members of the Wnt
family, shown to be up-regulated in many cancers, the
role of Wnt 5a is still controversial. While it has been
attributed a tumour suppressor function in some malig-
nancies, there is increasing evidence of promigratory and
proinvasive effects in others, mediated predominantly
through the planar cell polarity pathway and activation of
protein kinase C [26,27]. In our experimental setting,
transcription of WNT-5A was down-regulated in stage 2
DNA Arrays Figure 1
DNA Arrays: PhosphorImager output of the two Clontech Atlas™ Human Cancer cDNa Expression Array nylon filters after 
hybridization with 32P-labeled cDNA derived from total RNA from either NSCLC patients at stage 1 and stage 2 (Panels A and 
B, respectively).
A B
Table 3: Primers and conditions utilized for the Quantitative RT-PCR
Gene Sequence PCR product (bp) Annealing Temp.
Cyc D1 for TGAGGCGGTAGTAGGACAGG 66 60°C
Cyc D1 rev GACCTTCGTTGCCCTCTGT
VEGF for GCAGTAGCTGCGCTGATAGA 119 60°C
VEGF rev CCTTGCTGCTCTACCTCCAC
WNT-5A for CAAAGCAACTCCTGGGCTTA 107 60°C
WNT-5A rev GCTCGGATTCCTCGGCT
MMP11 for CAGCCAAAGAAGTCAGGACC 147 60°C
MMP11 rev GGTGCCCTCTGAGATCGAC
Rb2/p130 for AGGAGTTTCTCCTGTGCGTATC 106 60°C
Rb2/p130 rev TGAAACAATGCTTTCTCCTCG
Semaphorin for TCACAGTGGCAGCATAGAGG 111 60°C
Semaphorin rev TCACAGTGGCAGCATAGAGG
Decorin for TGCAGGTCTAGCAGAGTTGTGT 91 60°C
Decorin rev AATGCCATCTTCGAGTGGTC
XRCC1 for GACACTTACCGAAAATGGCG 110 60°C
XRCC1 rev GACACTTACCGAAAATGGCGJournal of Experimental & Clinical Cancer Research 2008, 27:38 http://www.jeccr.com/content/27/1/38
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NSCLC, thus underlying a putative tumour suppressor
function of its gene product in lung cancer progression.
The MMP11 gene belongs to a family of matrix metallo-
proteinases, proteolytic enzymes that degrade extracellu-
lar matrix and promote the local or metastatic potential of
carcinoma cells, and whose action is restrained by special
inhibitors (metalloproteinase inhibitors) [28,29]. The
role of MMP11 protease in lung cancer progression has
been clearly defined [28,29].
The Rb2/p130 gene codes for one of the retinoblastoma-
related proteins. Its role as tumour-suppressor is well doc-
umented [30,31], as well as its involvement in lung cancer
progression [14]. Our data further suggest that alteration
on Rb2/p130 gene expression is involved also in the ini-
tial steps of NSCLC progression.
Loss of Semaphorin-A3F genes occurs frequently in lung
cancer and correlates with advanced stage of disease [32].
Moreover, in lung cancer patients, semaphoring gene loss
correlates with advanced disease and increased VEGF
binding to tumour cells [33,34]. Our data confirms this
phenomenon and correlates it also to the initial step of
NSCLC progression.
The Decorin gene codes for one of the major extracellular
matrix protein which has become the focus of various can-
cer studies [35]. The exact biological role of decorin in
cancer has yet to be clarified; however, several experimen-
tal data suggest its involvement in cancer progression and
metastatization [36].
The XRCC1 gene codes for a base excision repair. Several
papers have investigated the association between lung
cancer and genetic polymorphisms in XRCC1, suggesting
a predisposition to lung cancer development for the
patients carrying these gene alterations [37,38]. Interest-
ingly, it has been recently described that XRCC1 transcript
abundance levels correlate with cisplatin chemoresistance
in non-small cell lung cancer cell lines [39]. To the best of
our knowledge, no previous report exists about the
involvement of the XRCC1 gene in the early steps of
NSCLC progression.
Conclusion
This study confirms the aptitude of the cDNA array tech-
nology in defining molecular pathways involved in
NSCLC progression. In addition, our results corroborated
previously observed expression patterns of a series of
genes, and revealed new genes differentially expressed
during NCSLC progression. The role of these newly iden-
tified genes is being evaluated in further studies analyzing
protein expression pattern and function of the proteins in
vitro and in vivo in lung cancer cells.
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